Interventions for Promoting Kidney Transplant Empowerment
Recruiting now · Not applicable
Conditions studied: Kidney Transplant Waitlisting
In brief
This is a cluster randomized controlled clinical trial evaluating the effect of community health workers (CHWs) and provider education on kidney transplant (KTx) waitlisting compared to usual care (waitlist control). CKD/HD providers will be randomized to intervention or control, and all patients with the same providers will be in the same randomization group. CHWs will address unmet social needs and patient symptoms through evaluations and linkage to clinical and community services. Intervention providers will receive education, which will include training on working with CHWs, reducing bias in clinical decision-making, and increasing affirming/reducing stigmatizing language in electronic health records (EHRs).
Key facts
- Study ID
- NCT06655857
- Run by
- Icahn School of Medicine at Mount Sinai
- People needed
- 5
- Starts
- 2025-08-05
- Expected to finish
- 2027-12-29
- Last updated by the study team
- 2026-05-01
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patient inclusion:
- Provision of signed and dated informed consent from the patient.
- Stated willingness to comply with all study procedures and availability for the duration of the study.
- Age 18 - 75 years
- eGFR≤20 mL/min/1.73m2 or on maintenance in-center HD.
- Receive kidney care at Mount Sinai, Einstein, Bellevue Hospital, NYU, or hemodialysis at a participating HD Center.
- Community dwelling (i.e., not in a nursing home, currently incarcerated).
- Speak English and/or Spanish.
- Provider Inclusion:
- Provision of signed and dated informed consent from the nephrologist.
- Stated willingness to comply with all study procedures and availability for the duration of the study.
You may not qualify if…
- Patient Exclusion:
- Absolute contraindications to KTx:
- Self-reported or documented diagnosis of dementia, or inability to understand the study and complete informed consent. When the participant's understanding is unclear, the CRC will use a modified MOCA screener to determine eligibility.
- Active malignancy (excluding local non-melanoma skin cancer, renal cell carcinoma <5 cm, early thyroid cancer, and prostate cancer GS≤6).
- Pregnancy (can be re-evaluated post-delivery).
- Active infection. Patients excluded due to active infection will be evaluated at 30 days or after completing full treatment (whichever is later) to determine eligibility. Examples of active infection include:
- Positive cultures or radiographic evidence of infection
- Infected intravascular devices, such as tunneled catheters and pacemakers
- Active histoplasmosis, cryptococcosis, tuberculosis (TB), and nontuberculous mycobacteria
- Previously evaluated by KTx and not listed for specific medical reasons.
- Patients previously evaluated and not listed will be carefully reviewed by site PI for eligibility
- Already listed for KTx.
- Patients on other types of dialysis other than in-center hemodialysis.
- Self-identify as already engaged with a CHW at participating sites to address unmet social needs.
- Planning to move out of the greater NY area in the next 1 year.
- Provider Exclusion:
- Planning to leave their respective institutions in the next 1 year
Where it is running
- Mount Sinai Hospital — New York, New York, United States (enrolling)
- NYU Langone Health — New York, New York, United States
- Montefiore Einstein — The Bronx, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.